227 related articles for article (PubMed ID: 35368240)
1. Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options.
Tan CS; Ngo WK; Chay IW; Ting DS; Sadda SR
Clin Ophthalmol; 2022; 16():917-933. PubMed ID: 35368240
[TBL] [Abstract][Full Text] [Related]
2. Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration.
ElSheikh RH; Chauhan MZ; Sallam AB
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358978
[TBL] [Abstract][Full Text] [Related]
3. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
Park DH; Sun HJ; Lee SJ
Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
[TBL] [Abstract][Full Text] [Related]
4. Value of Anti-Vascular Endothelial Growth Factor Gene Therapy for Neovascular Age-Related Macular Degeneration.
Berkowitz ST; Patel S
Ophthalmol Retina; 2021 Apr; 5(4):357-364. PubMed ID: 32818623
[TBL] [Abstract][Full Text] [Related]
5. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: systematic review and Bayesian network meta-analysis.
Ye L; Jiaqi Z; Jianchao W; Zhaohui F; Liang Y; Xiaohui Z
Ther Adv Chronic Dis; 2020; 11():2040622320953349. PubMed ID: 32953000
[TBL] [Abstract][Full Text] [Related]
7. Twenty Years of Anti-Vascular Endothelial Growth Factor Therapeutics in Neovascular Age-Related Macular Degeneration Treatment.
Moon BH; Kim Y; Kim SY
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629185
[TBL] [Abstract][Full Text] [Related]
8. Complete RPE and outer retinal atrophy in patients receiving anti-VEGF treatment for neovascular age-related macular degeneration.
Eng VA; Rayess N; Nguyen HV; Leng T
PLoS One; 2020; 15(5):e0232353. PubMed ID: 32369500
[TBL] [Abstract][Full Text] [Related]
9. Emerging Treatment Modalities for Neovascular Age-Related Macular Degeneration: A Systematic Overview.
Balatsoukas DD; Tsaousis KT; Boboridis KG; Konstas AG; Topouzis F
Adv Ther; 2022 Jan; 39(1):5-32. PubMed ID: 34724151
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept.
Sato T; Enoki T; Karasawa Y; Someya H; Taguchi M; Harimoto K; Takayama K; Kanda T; Ito M; Takeuchi M
Front Immunol; 2021; 12():738521. PubMed ID: 34721402
[TBL] [Abstract][Full Text] [Related]
11. Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials.
Yamashiro K; Oishi A; Hata M; Takahashi A; Tsujikawa A
Jpn J Ophthalmol; 2021 Nov; 65(6):741-760. PubMed ID: 34491474
[TBL] [Abstract][Full Text] [Related]
12. New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD).
Patel P; Sheth V
J Clin Med; 2021 May; 10(11):. PubMed ID: 34070899
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal injectable hydrogel rods with long-acting bevacizumab delivery to the retina.
Lee S; Hong HK; Song JS; Jeong SI; Chung JY; Woo SJ; Park KD
Acta Biomater; 2023 Nov; 171():273-288. PubMed ID: 37739248
[TBL] [Abstract][Full Text] [Related]
14. Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration.
Quist SW; de Jong LA; van Asten F; Knoester P; Postma MJ; Freriks RD
Graefes Arch Clin Exp Ophthalmol; 2022 Apr; 260(4):1083-1095. PubMed ID: 34643793
[TBL] [Abstract][Full Text] [Related]
15. [Electrophysiological study of the visual pathway in anti-VEGF therapy of neovascular age-related macular degeneration combined with glaucoma].
Smirnova TV; Rud'ko AS; Andreeva IV; Karpilova MA
Vestn Oftalmol; 2019; 135(5):38-45. PubMed ID: 31714511
[TBL] [Abstract][Full Text] [Related]
16. New Therapies of Neovascular AMD-Beyond Anti-VEGFs.
Yerramothu P
Vision (Basel); 2018 Jul; 2(3):. PubMed ID: 31735894
[TBL] [Abstract][Full Text] [Related]
17. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
Nguyen QD; Das A; Do DV; Dugel PU; Gomes A; Holz FG; Koh A; Pan CK; Sepah YJ; Patel N; MacLeod H; Maurer P
Ophthalmology; 2020 Jul; 127(7):963-976. PubMed ID: 32107066
[TBL] [Abstract][Full Text] [Related]
18. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems.
Finger RP; Daien V; Eldem BM; Talks JS; Korobelnik JF; Mitchell P; Sakamoto T; Wong TY; Pantiri K; Carrasco J
BMC Ophthalmol; 2020 Jul; 20(1):294. PubMed ID: 32680477
[TBL] [Abstract][Full Text] [Related]
19. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration.
Hussain RM; Ciulla TA
Expert Opin Emerg Drugs; 2017 Sep; 22(3):235-246. PubMed ID: 28756707
[TBL] [Abstract][Full Text] [Related]
20. Long acting delivery and therapies for neovascular age-related macular degeneration.
Rowe LW; Ciulla TA
Expert Opin Biol Ther; 2024 Jul; ():. PubMed ID: 38953649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]